key: cord-0955863-ez4v8xr0 authors: Sterlin, D.; Mathian, A.; Miyara, M.; Mohr, A.; Anna, F.; Claer, L.; Quentric, P.; Fadlallah, J.; Ghillani, P.; Gunn, C.; Hockett, R.; Mudumba, S.; Guihot, A.; Luyt, C.-E.; Mayaux, J.; Beurton, A.; Fourati, S.; Lacorte, J.-M.; Yssel, H.; Parizot, C.; Dorgham, K.; Charneau, P.; Amoura, Z.; Gorochov, G. title: IgA dominates the early neutralizing antibody response to SARS-CoV-2 date: 2020-06-11 journal: nan DOI: 10.1101/2020.06.10.20126532 sha: e043efe8ce170f6bb92710ccc21c1302f95d032b doc_id: 955863 cord_uid: ez4v8xr0 A major dogma in immunology has it that the IgM antibody response precedes secondary memory responses built on the production of IgG, IgA and, occasionaly, IgE. Here, we measured acute humoral responses to SARS-CoV-2, including the frequency of antibody-secreting cells and the presence of specific, neutralizing, antibodies in serum and broncho-alveolar fluid of 145 patients with COVID-19. Surprisingly, early SARS-CoV-2-specific humoral responses were found to be typically dominated by antibodies of the IgA isotype. Peripheral expansion of IgA-plasmablasts with mucosal-homing potential was detected shortly after the onset of symptoms and peaked during the third week of the disease. While the specific antibody response included IgG, IgM and IgA, the latter contributed to a much larger extent to virus neutralization, as compared to IgG. However, specific IgA serum levels notably decrease after one month of evolution. These results represent a challenging observation given the present uncertainty as to which kind of humoral response would optimally protect against re-infection, and whether vaccine regimens should consider boosting a potent, although, at least in blood, fading IgA response. Patients achieved a seroconversion within 20 days after symptoms onset, although with different kinetics of IgM and IgG production (2) (3) (4) . Secretory IgA plays a crucial role in protecting mucosal surfaces against pathogens by neutralizing respiratory viruses or impeding their attachment to epithelial cells (5) (6) (7) (8) . It has been demonstrated that influenza-specific IgA is more effective to prevent infections in mice and human than specific IgG. Elevated IgA serum levels have been correlated with influenza vaccine efficacy (9-11). IgA might also play an important role in SARS-CoV infections. In mice, an intranasal delivery system of SARS-CoV proteins provide a better protection against SARS-CoV challenge than intramuscular administrations, suggesting that mucosal-induced IgA contributes efficiently against viral infection (12). A recently reported intervention based on an intranasal immunization with a MERS-derived vaccine confirmed the beneficial role of IgA (13). However, to which extent IgA production steps in to control natural SARS-CoV-2 infection in humans remains poorly understood. Here, we tracked antibody-secreting cells in blood of SARS-CoV-2-infected patients. We then determined specific antibody titers in serum and studied their neutralizing capacities. Our results show that human IgA antibodies are often detectable before the appearance of SARS-CoV-2-specific IgG and argue in favor of a key role for IgA antibodies in early virus neutralization. The rapid, albeit transient, appearance of plasmablast in the blood circulation is a typical feature of the acute phase of viral infections (14). We longitudinally monitored phenotypic changes of B cells in the blood of 38 SARS-CoV-2-infected patients (Table S1) Figure 1D ), a feature consistent with a mucosal phenotype for these cells. Intracellular IgA subclass identification showed higher frequencies of IgA1-expressing plasmablasts, as compared to IgA2 (66 [26.8-88 .5]% IgA1 + vs 31.6[3.7-70.8]% IgA2 + in IgA + plasmablasts; n=13; Figure S1B-C). This first wave of circulating IgA-expressing plasmablasts was followed by a second wave of IgG-expressing cells that became predominant by day 22 after the onset of symptoms ( Figure 1E , S1D-E). While the majority of IgA + expressed CCR10, this marker was expressed by only a minority of IgG + plasmablasts (60.5[37.6-92.6]% vs 23.3[3.2-78]% CCR10+, n=15; Figure S1F ), suggesting that the latter may niche differently, and most likely in the bone marrow. Of note, the frequency of peripheral IgM-expressing plasmablasts did not significantly vary with time ( Figure S1G ) and only marginally at later time points ( Figure S1H ). In a recent study that characterized the immune response of a COVID-19 patient, the induction of T follicular helper (Tfh) cells was reported to occur concomitantly with that of plasmablasts (17). In order to evaluate a potential germinal center origin of the plasmablast wave observed in our patients, we longitudinally tracked CD4 + CXCR5 + PD1 +/-Tfh cells in their blood. We found no significant increase in the frequency of Tfh subsets in COVID-19 patients, as compared to healthy donors, at any of the analyzed time points ( Figure S2A -B). Neither activated (CD4 + CXCR5 + PD1 + ), nor latent (CD4 + CXCR5 + PD1 -), Tfh cells were correlated with plasmablasts frequency ( Figure S2C ). The frequency of neither activated (CD4 + CXCR5 + PD1 + ), nor latent (CD4 + CXCR5 + PD1 -) Tfh cells was found to correlate with that of plasmablasts. ( Figure S2C ). Taken together, these results point toward an early humoral response to SARS-CoV-2 dominated by IgA-expressing plasmablasts, circulating across mucosal sites. Photonic ring immunoassay is a novel technology that allows to simultaneously test in parallel various antigens ( Figure S3 ) (18, 19) . Using this technique, we assessed the prevalence of IgG, IgA and IgM antibodies recognizing the SARS-CoV-2 full-length nucleocapsid protein (NC) or Spike Receptor-binding domain (S1-RBD) in 214 serum samples of 135 infected patients (Tables S2 and S3 ). The appearance of IgA or IgG antibodies directed at SARS-CoV-2 S1-RBD was detected, in only three cases, as early as day 1 and 2 after the onset of the first symptoms, respectively ( Figure S4 ). Anti-S1-RBD IgG and IgA were detected in 7 and 15 out of 48 samples, respectively, during the first week ( Figure 2A and Figure S4 ). Although IgM is typically considered as a marker of acute infection, anti-S1-RBD IgM were detected only in 7 out of these 48 early samples (Figure 2A and Figure S4 ). Moreover, anti-NC IgM remained undetectable in all samples except one. The proportion of patients with detectable anti-S1-RBD IgG increased until reaching a plateau approximately during the fourth week after symptoms onset (positive samples: 15% day 1-7; 42% day 8-14; 74% day 15-21; 90% day 22-28 and 92% day>28; Figure 2A -B). In contrast, the frequency of patients with anti-S1-RBD IgA peaked around day 22 (positive samples: 31% day 1-7; 51% day 8-14; 72% day 15-21 and 80% day 22-28; Figure 2A -B), then decreased by day 25 (positive samples: 23% day>28 ; Figure 2A -B). Following a similar kinetics with respect to the appearance of anti-S1-RBD antibodies, the proportion of patients with detectable anti-NC IgG remained stable around the fourth week post-symptoms onset (positive samples: 15% day 1-7; 56% day 8-14; 85% day 15-21; 90% day 22-28 and 89% day>28 ; Figure 2A -B) whereas anti-NC IgA quickly disappeared and were no longer detectable in most patients one month after disease onset (positive samples: 23% day 1-7; 52% day 8-14; 67% day 15-21; 65% day 22-28 and 8% day>28 ; Figure 2A -B). Of note, in All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20126532 doi: medRxiv preprint two patients who recovered from COVID-19, no specific antibodies were detected at the available late time-points ( Figure 2A ). Both anti-S1-RBD and anti-NC IgG titers increased over time (anti-S1-RBD arbitrary units: Figure 2A ) while virus-specific IgA titers rised during the first 3 weeks after symptoms onset, then dropped and were undetectable one month after recovery (anti-S1-RBD arbitrary units: Figure 2A ). Altogether, these results suggest that anti-SARS-CoV-2 IgA testing should improve early COVID19 diagnosis, while testing serum more than 28 days after the onset of symptoms should mainly rely on the detetion of IgG antibodies. We then sought to determine the respective contribution of each of the IgG and IgA isotypes to virus neutralization. We assessed the neutralizing capacity of serum antibodies using a pseudoneutralization assay. The neutralization potential of serum, tested at dilution 1/40 according to previous studies rapidly increased during disease course, and plateaued by day 10 post-symptoms onset ( Figure 3A and Figure S5A ). Neutralizing activity, determined in 12 sera having reached this plateau, was found to vary considerably between patients with half maximal inhibitory concentration (IC 50 ) values ranging from 1/169 to 1/16189 serum dilution ( Figure S5B ). To detail the respective contributions of the dominant antibody isotypes to virus neutralization, purified IgA and IgG fractions from the serum of 12 patients ( Figure 3B ) were back-to-back tested for their neutralizing capacity ( Figure 3C , D). Strikingly, IgA were far more potent in their capacity to neutralize SARS-CoV-2, as compared to paired IgG ( Figure 3C Figure 3E ). In our cohort, two profiles of sera could be distinguished based on their high or low IgA neutralization potential ( Figure 3D ). Interestingly, these profiles were directly associated with lower or higher anti-S1-RBD IgA serum titers, respectively (6.5[3.1-11.1] vs 21.6[7.9-38.9], n=12, p=0.02; Figure 3F ), suggesting that, as expected, IgA neutralisation potential is mainly relying on RBD targeting. Importantly, the more efficient neutralisation potential of IgA compared to IgG cannot be explained by an avidity effect, as both purified antibody preparations were monomeric ( Figure 3B ). These observations highlight the neutralization potential of systemic humoral immunity driven by both IgA and IgG. However, the main SARS-CoV-2 targets are lung epithelial cells (20, 21) , and mucosal immunity differs from systemic immunity. Therefore, to assess local immunity, bronchoalveolar lavage (BAL) samples obtained from 10 patients (Table S4) were tested for their neutralization potential ( Figure 3G ). As shown, BAL samples harvested at various times, and as early as 4 days after symptoms onset, harbored detectable SARS-CoV-2 neutralization activity, suggesting the mounting of an efficient local immune response as well. Of note, IgG concentrations were always superior than those of IgA in the tested BAL samples, except one ( Figure 3H ). We have studied the antibody response of COVID-19 patients and show that SARS-CoV-2 infection induces an early and potent virus-specific IgA response that precedes the production All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20126532 doi: medRxiv preprint of SARS-CoV-2 IgG. Importantly, IgA antibodies purified from the serum of these patients were found to more efficiently neutralize SARS-CoV-2 in vitro than IgG. However, we also observed a rapid decline in SARS-CoV-2-specific IgA serum levels, thereby questioning the long-term efficacy of this first wave response, as efficient as it appears to be. It remains nevertheless possible that sustained SARS-CoV-2-specific secretory IgA levels are maintained in secretions, and particularly in the pulmonary lumen. Indeed, previously documented re-circulating IgA-secreting plasmablasts with a mucosal-homing profile were detected in high numbers in the patients we studied, and could seed their lung/airway interface (16, [22] [23] [24] . It is also known that IgA-secreting cells efficiently home to and reside within human mucosa (25) , and that IgA subclass switch recombination can directly take place in this tissue (26) in a T cell-independent manner (27) . The lack of correlation between plasmablast and Tfh cell expansion, observed in the present study, could argue in favor of a prominent germinal center-independent induction of IgA (28) . Of note, several recently described SARS-CoV-2 neutralizing IgG (29, 30) were devoid of somatic mutations typically associated with affinity maturation and T cell help. In this respect, a molecular and functional characterisation of IgA monoclonal antibodies secreted by plasmablasts accessible in blood during the first week of symptoms should shed light on their mutational status. The observation made in our study could also give clues to explain the puzzling observation that the vast majority of children are not afffected by COVID-19 (31, 32) , by postulating that cross-reactive IgA, recently identified in human gut mucosa against other targets than SARS-CoV-2 (22, 33) , might be more prevalent in children and/or could be rapidly mobilized in response to infection with SARS-CoV-2. The BAL samples tested in this study were obviously obtained from severe COVID-19 patients, all affected with severe lung damage, and therefore possible serum contamination. It remains to be confirmed whether the BAL IgG prevalence observed ( Figure 3H ), is representative of the pulmonary humoral status of mild and convalescent patients. To address this issue, it is important to evaluate, in future studies, the presence of SARS-CoV-2-specific secretory IgA at easily accessible sites, such as in saliva from COVID-19-recovered patients. Saliva probing might become technically feasible given the exquisite sensitivity of novel digital ELISA-based assays for SARS-CoV-2-specific IgA detection (34) . Future studies will also confirm the suitability of the photonic ring immunoassay technology, used in the present study, for the detection of IgA in saliva. The latter approach could represent an attractive alternative for the mass testing programs that need to be implemented, given that results are rapidly obtained using a small-size fully automated instrument, and only a few microliters of sample volume. It is also important to note that in some of the early serum samples with efficient virus neutralizing capacity, only anti-RBD IgM, but neither IgA nor IgG SARS-CoV-2 spike RBDspecific antibodies were above the detection threshold (P2 day 14 and P3 day 6 post symptoms, Figure S5C ). This observation points to a protective potential for IgM as well. The latter sequence (M first, then G and A) is however not likely to be prevalent. A more typical profile is exemplified by patient P9, with anti-RBD IgA levels peaking before the appearance of anti-RBD IgG, and barely detectable IgM at any time point ( Figure S5C ). Since, in rare cases, only specific IgM are detected at early time points, it remains recommended to measure the presence of all isotypes for serological diagnosis. Our study presents several limitations. Functional mucosal immunity analysis was only carried out in BAL, and longitudinal studies are needed at various body sites in order to assess whether local SARS-CoV-2-specific IgA production might be more persistant than in blood. In addition, it remains to be confirmed whether the in vitro IgA neutralization efficacy of the purified IgA serum antibodies translates into a potent barrier effect, not only in recovered patients, but also in paucisymptomatic individuals and healthy carriers. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . In conclusion, we would like to stress the importance of mucosal immunity as an important defence mechanism against SARS-CoV-2 to be monitored in infected patients, as well as to recommend testing the usefulness of a vaccine protocol aimed at inducing a specific respiratory IgA response to SARS-CoV-2. Table S1 . Phenotyping was assessed on freshly isolated PBMCs stained with a combination of antihuman antibodies (Table S5) . Intracellular staining was performed on fixed and permeabilized cells (using the FOXP3 Transcription Factor Staining Buffer kit, eBioscience). Cells were acquired on a BD FACSCanto II Flow cytometer (BD biosciences) and analysed with FlowJo v10 software (FlowJo, LLC). SARS-CoV-2 antigens: nucleocapsid, Spike S1 RBD, Spike S1S2, Spike S2 and Spike S1 with in a multiplex format based on photonic ring resonance technology (18, 19, 35) . This system detects and measure with good reproducibility ( Figure S3 ) changes in resonance when antibodies bind to their respective antigens in the chip. The instrument automates the assay. Briefly, 10µl of each serum samples were added in a sample well plate array containing required diluents and buffers. The plate and chip are loaded in the instrument. First the chip is equilibrated with the diluent buffer to get baseline resonance. Serum sample is then charged over the chip to bind specific antibodies to antigens present on the chip. Next, chip is washed to remove low affinity binders. Finally, specific antibodies of patients are detected with anti-IgG or -IgA or -IgM secondary antibodies. 20 sera collected before December 2019 were analyzed to calculate cut-off values. Positivity was defined as results above the 99 th percentile. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20126532 doi: medRxiv preprint IgA and IgG were isolated from 12 serum samples diluted in 1X-PBS as previously described (33) . Sera were selected after SARS-CoV-2 specific antibodies evaluation. Briefly, serum samples were load onto peptide M/Agarose or Protein G/Agarose column (Invivogen) after column equilibration. Chromatography steps were performed at a flow rate of 0.5ml/min. Next, 20 column volumes of 1X-PBS was used to wash the column. IgA and IgG were then eluted with 5ml of 0.1M glycine (Sigma-Aldrich) and pH was immediately adjusted to 7.5 with 1M Tris. 1X-PBS buffer exchange was achieved using Amicon® Ultra centrifugal filters (Merck Millipore) through a 100-kD membrane according to the manufacturer's instructions. The quantification of IgA and IgG was determining using NanoVue Plus microvolume spectrophotometers. First, serum dilutions are mixed and co-incubated with 300 TU of pseudotyped vector at room temperature during 30 minutes. Serum and vector are diluted in culture medium All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. After 48h, medium is removed and bioluminescence is measured using a Luciferase Assay System (Promega) on an EnSpire plate reader (PerkinElmer). Variables are expressed as the median. Nonparametric test were used as Mann-Whitney U test to compare two independent groups, Wilcoxon test to compare paired values and Spearman correlation test. Significant P values are indicated as described below: * p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Statistical analysis was performed using GraphPad Prism software, V6 (GraphPad, San Diego). (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20126532 doi: medRxiv preprint Representative flow cytometry analysis of B-cell subpopulations in the blood of SARS-CoV-2 infected patients. Doublets and dead cells were excluded before CD3- Intracellular IgA versus IgG expression in plasmablasts according to disease duration. Each dot represents one patient. Non-parametric Spearman correlation was calculated. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20126532 doi: medRxiv preprint Table S1 ) was determined by pseudovirus neutralisation assay. Orange curve represents significant sigmoidal interpolation (p=0.0082). Grey dotted lines represent 95% confidence intervals curves. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . Purified IgG and IgA are monomeric. Representative SDS-PAGE showing purified IgG and IgA in non-reducing conditions for P11 and P12. The same experiment was repeated for the 12 purified IgG and IgA pairs. C. Neutralizing activity of purified IgG was measured at indicated concentrations from 12 sera collected between day 11 and day 24 post-symptoms onset (as indicated). Curves were drawn according to non-linear regression. Table S4) . Indicated BAL dilutions were tested using pseudovirus neutralization assay. Bronchoalveolar lavages obtained from SARS-CoV-2 negative patients (n=3) showed no neutralization activity (dotted grey lines). Each colored line represent one patient. H. IgG and IgA levels measured by ELISA in bronchoalveolar lavages tested in panel F. P value was calculated using Mann-Whitney test (** p<0.01). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . Anti-S1-RBD IgA and IgG levels are measured in sera collected between day 1 and day 7 after symptoms onset (n=48). Antibody levels are expressed as arbitrary units/ml (AU/ml). Cut-off lines are represented as grey dotted lines. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. Anti-S1-RBD IgG Anti-S1-RBD IgM C All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20126532 doi: medRxiv preprint indicated time points (top arrows) are compared. IC 50 values measured in IgA and IgG purified at indicated time points are also indicated (bottom arrows). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20126532 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 11, 2020. . https://doi.org/10.1101/2020.06.10.20126532 doi: medRxiv preprint Genetic Recombination, and Pathogenesis of Coronaviruses Antibody responses to SARS-CoV-2 in patients with COVID-19 Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia SARS-CoV-2 receptor and entry genes are expressed by sustentacular cells in the human olfactory neuroepithelium Natural polyreactive IgA antibodies coat the intestinal microbiota A T cell-dependent mechanism for the induction of human mucosal homing immunoglobulin A-secreting plasmablasts Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells IgA subclass switch recombination in human mucosal and systemic immune compartments Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways Human neutralizing antibodies elicited by SARS-CoV-2 infection A human neutralizing antibody targets the receptor binding site of SARS-CoV-2 Chinese Pediatric Novel Coronavirus Study Team, SARS-CoV-2 Infection in Children Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children Human IgA binds a diverse array of commensal bacteria Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV Antibodies for Detecting Early Seroconversion in COVID-19 Patients, medRxiv Clinical optimization and multicenter validation of antigen-specific cut-off values on the INNO-LIA ANA update for the detection of autoantibodies in connective tissue disorders Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo Table S5: Human Antibodies used for B and T cell phenotyping Anti-hCD3 APC-H7 (clone SK7) BD Biosciences No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted The authors wish to thank the patients that agreed to participate in this study, doctors and nurses from the endocrinology, metabolism, nutrition and diabetology Departments of Institut All rights reserved. No reuse allowed without permission. (13) Values are expressed as n (%), unless stated otherwise. *including cardiac, liver or kidney allograft (n=9), hematopoietic stem cell transplantation (n=1), chemotherapy for cancer (n=6) or immunosuppressant for auto-immune disease (n=12) † Excluding antimalarials and prednisone. Immunosuppressant therapy was mycophenolate mofetil for 9 patients, tacrolimus or cyclosporine for 9, methotrexate for 3, everolimus for 2, rituximab for one and ustekinumab for one. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Laboratory findings at baseline* White blood cells count /mm 3 , median (range) 11.2 (5.0 -26.5) Neutrophils count /mm 3 , median (range) 9.9 (4.8 -19.6) Lymphocytes count /mm 3 , median (range) 0.9 (0.1 -1.6) Lactate Deshydrogenase U/l, median (range) 541 (402 -817) Ferritin µg/l, median (range) 1746 (235 -4640) D-dimers ng/ml, median (range) 15360 (580 -20000)Time from illness onset to admission in ICU, days, median (range) 10 (5 -14) Time from admission in ICU to BLA, days, median (range) 3 (1 -9) Lymphocytes count/mm 3 , median (range) 41 (12-516) Neutrophils count/per field 1 to 9 9 (90) 10 to 25 1 (10) SARS-Cov-2 real-time reverse transcription-PCR analysis 10 (100) Other viruses 1 (10) Bacteria 1 (10) Fungus 0 (0) Invasive mechanical ventilation 10 (100) Extracorporeal membrane oxygenation 7 (70)